Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 1,238 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,238 shares of the business’s stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $93.14, for a total value of $115,307.32. Following the sale, the chief financial officer now directly owns 69,408 shares in the company, valued at approximately $6,464,661.12. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, May 1st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The stock was sold at an average price of $93.97, for a total value of $175,348.02.
• On Thursday, April 25th, Michael Burkes Brophy sold 705 shares of Natera stock. The shares were sold at an average price of $89.55, for a total value of $63,132.75.
• On Tuesday, April 23rd, Michael Burkes Brophy sold 1,523 shares of Natera stock. The stock was sold at an average price of $91.38, for a total value of $139,171.74.
• On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The shares were sold at an average price of $92.62, for a total transaction of $127,630.36.
• On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The shares were sold at an average price of $90.42, for a total transaction of $82,643.88.
• On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The shares were sold at an average price of $88.36, for a total transaction of $249,705.36.
• On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The stock was sold at an average price of $70.03, for a total transaction of $2,383,050.87.
• On Thursday, February 1st, Michael Burkes Brophy sold 22,281 shares of Natera stock. The stock was sold at an average price of $67.73, for a total value of $1,509,092.13.

Natera Price Performance

Natera stock opened at $96.98 on Friday. The firm has a fifty day moving average of $90.56 and a 200-day moving average of $69.29. Natera, Inc. has a 52-week low of $36.90 and a 52-week high of $98.82. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $11.86 billion, a P/E ratio of -25.59 and a beta of 1.38.

Natera (NASDAQ:NTRA) last issued its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.09. The company had revenue of $311.11 million during the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. As a group, analysts predict that Natera, Inc. will post -2.35 EPS for the current year.

Institutional Trading of Natera

Several large investors have recently bought and sold shares of NTRA. FDx Advisors Inc. grew its holdings in Natera by 17.1% during the 1st quarter. FDx Advisors Inc. now owns 5,109 shares of the medical research company’s stock valued at $467,000 after purchasing an additional 747 shares in the last quarter. Chevy Chase Trust Holdings LLC acquired a new position in shares of Natera in the first quarter worth about $14,467,000. GSA Capital Partners LLP boosted its holdings in Natera by 41.8% in the first quarter. GSA Capital Partners LLP now owns 28,222 shares of the medical research company’s stock valued at $2,581,000 after purchasing an additional 8,319 shares during the last quarter. RiverPark Advisors LLC grew its stake in Natera by 581.8% during the 1st quarter. RiverPark Advisors LLC now owns 2,952 shares of the medical research company’s stock valued at $270,000 after purchasing an additional 2,519 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. acquired a new stake in Natera during the 1st quarter valued at approximately $33,938,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on NTRA. Raymond James downgraded shares of Natera from a “strong-buy” rating to an “outperform” rating and boosted their target price for the company from $68.00 to $85.00 in a research note on Tuesday, February 20th. StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a research note on Wednesday. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price for the company in a research note on Friday, April 5th. Craig Hallum assumed coverage on Natera in a research note on Monday, April 8th. They set a “buy” rating and a $117.00 price target on the stock. Finally, The Goldman Sachs Group lifted their price objective on Natera from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, April 15th. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average price target of $86.40.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.